IND Swift Laboratories Ltd
NSE:INDSWFTLAB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
IND Swift Laboratories Ltd
NSE:INDSWFTLAB
|
11.6B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
IND Swift Laboratories Ltd
Glance View
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm operates through the bulk drugs and pharmaceuticals segment. Its business includes Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The firm has a product portfolio of approximately 12 therapeutic segments. The company is manufacturing APIs of complex therapies namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Multidisciplinary skills Synthetic Medicinal Chemistry Custom Synthesis Process R&D cGMP Manufacturing Analytical Development Regulatory Support Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. The Company’s products and services include API products, custom chemicals, and impurities. The firm manufacturing facilities are at Derabassi and Jammu Kashmir.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for IND Swift Laboratories Ltd is 51.6%, which is above its 3-year median of 46.2%.
Over the last 3 years, IND Swift Laboratories Ltd’s Gross Margin has increased from 43.8% to 51.6%. During this period, it reached a low of 37.9% on Mar 31, 2023 and a high of 51.6% on Jan 1, 2026.
